SLC41A1: A Potential Drug Target and Biomarker (G254428)

Target Name: SLC41A1

NCBI ID: G254428

SLC41A1

SLC41A1: A Potential Drug Target and Biomarker

SLC41A1 (Solute carrier family 41 member 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the SLC41 family, which is known for its role in transporting small molecules across cell membranes. SLC41A1 has been identified as a potential drug target or biomarker due to its unique structure and the involvement of multiple diseases.

The SLC41A1 protein is composed of 254 amino acid residues and has a calculated molecular mass of 31.1 kDa. It is a type I transmembrane protein, which means that it spans the cell membrane and is involved in the delivery of various substances across the membrane. The protein has a unique feature called a putative N-terminal hypervariable region (HVR), which is a region of the protein that can vary in different species.

One of the unique aspects of SLC41A1 is its structure. The protein has a high degree of homogeneity, which means that it has a similar structure throughout its length. This is unusual for a protein that is so large, as it suggests that the protein has a highly conserved sequence. The SLC41A1 protein also has a unique fold, which is a structure that results from the arrangement of the amino acid residues in the protein. The fold is important because it determines the structure and function of the protein.

SLC41A1 has been involved in multiple diseases, including cancer, neurodegenerative diseases, and kidney disease. It is a known carrier protein for various ions, including sodium, potassium, and calcium. In addition, SLC41A1 has been shown to be involved in the transport of various molecules, including neurotransmitters and toxins.

SLC41A1 has also been identified as a potential drug target. The protein is known to be involved in the regulation of ion channels, which are responsible for the flow of charged particles through the cell membrane. This makes it a potential target for drugs that are designed to modulate ion channels. In addition, SLC41A1 is known to be involved in the regulation of various signaling pathways, which suggests that it may be a useful target for drugs that are designed to target signaling pathways in neurodegenerative diseases.

SLC41A1 has also been identified as a potential biomarker for several diseases. Its unique structure and the involvement of multiple diseases make it an attractive candidate for use as a biomarker. For example, SLC41A1 has been shown to be elevated in the blood and urine of individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that SLC41A1 may be a useful biomarker for these diseases. In addition, SLC41A1 has also been shown to be elevated in the urine of individuals with cancer, which suggests that it may be a useful biomarker for cancer.

In conclusion, SLC41A1 is a protein that is expressed in various tissues of the body and has been identified as a potential drug target and biomarker. Its unique structure and the involvement of multiple diseases make it an attractive candidate for both research and clinical applications. Further research is needed to fully understand the role of SLC41A1 in the regulation of ion channels and signaling pathways, as well as its potential as a biomarker for various diseases.

Protein Name: Solute Carrier Family 41 Member 1

Functions: Na(+)/Mg(2+) ion exchanger that acts as a predominant Mg(2+) efflux system at the plasma membrane (PubMed:22031603, PubMed:23661805, PubMed:18367447, PubMed:23976986). Transporter activity is driven by the inwardly directed electrochemical gradient for Na(+) ions, thus directly depends on the extracellular Na(+) ion concentration set by Na(+)/K(+) pump (PubMed:22031603, PubMed:23661805). Generates circadian cellular Mg(2+) fluxes that feed back to regulate clock-controlled gene expression and metabolism and facilitate higher energetic demands during the day (PubMed:27074515). Has a role in regulating the activity of ATP-dependent enzymes, including those operating in Krebs cycle and the electron transport chain (By similarity)

The "SLC41A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC41A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets